Liver Diseases Therapeutics Market Size, Share & Trends 2031
Liver Diseases Therapeutics Market Size, Share & Trends 2031
Segments - Liver Diseases Therapeutics Market by Products (Vaccines, Antiviral Drugs, Targeted Therapy, Immunosuppressants, Chemotherapy, Immunoglobulins, and Corticosteroids) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-2443
| 4.1 Rating
| 81 Reviews
| 225 Pages
| Format :
Report Description
Liver Diseases Therapeutics Market Outlook
The global liver diseases therapeutics market size was valued at USD 23.09 Billion in 2022 and is likely reach to USD 38.03 Billion by 2031, expanding at a CAGR of 5.7% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing incidences of hepatocellular carcinoma and other chronic diseases.
Liver disease is inherited or is caused by various elements that damage the liver due to excessive usage of alcohol or the virus infection. If the disease is not timely treated, it can damage the liver that further leads to liver failure.
Thus, some of the key drugs are used in the diagnosis of several types of liver diseases that include immunosuppressants, vaccines, antiviral drugs, and chemotherapy drugs. The presence of vaccination campaigns introduced by the governments and key major companies are spreading awareness about the diseases and its preventions.
For instance, the China Government spent over USD 420 million to inoculate nearly 140 million unvaccinated children in 2011. In the U.S., the Affordable Care Act was focusing on the expansion of access to diagnosis, viral hepatitis prevention, and treatment and care.
The COVID-19 pandemic directly cause to rapid surge in liver infection cases. The reason of liver injury by the COVID?19 can be driven by various factors including hypoxia, virus?induced systemic inflammation, drug-induced liver disease, and hepatic congestion.
In addition, the COVID?19 adversely affected outcomes of patients with chronic liver disease and accelerated the fatality rate of the COVID patients. Hence, there is a surge in the diagnosis, treatment, and follow-up of patients with liver disease, this has positively impacted the overall market revenue.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of hepatocellular carcinoma and other liver diseases along with the presence of huge unmet needs of patients worldwide are expected to boost the market in the coming years.
- Growing number of geriatric population globally is expected to drive the market growth during the forecast period.
- Strong pipeline by biotechnology and pharmaceutical companies are the key elements expected to enhance liver diseases therapeutics. This is projected to fuel the market growth during the forecast period.
- Rising number of vaccination programs introduced by several healthcare bodies and governments’ initiatives for spreading awareness about the diseases and prevention are expected to propel the market during the forecast period.
- Extensive R&D investments by major pharmaceutical companies in order to develop the study insights and new approaches are expected to accelerate the market expansion.
- Risks and adverse reactions linked with present clinical treatments and controlled FDA and other government approval norms are key challenges expected to hamper the market growth.
Scope of the Liver Diseases Therapeutics Market Report
The report on the global liver diseases therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Liver Diseases Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Products (Vaccines, Antiviral Drugs, Targeted Therapy, Immunosuppressants, Chemotherapy, Immunoglobulins, and Corticosteroids) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Astellas Pharma Inc.; Abbott Laboratories; Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc. |
Liver Diseases Therapeutics Market Segment Insights
Antiviral drugs segment is expected to grow at a rapid pace
Based on products, the global liver diseases therapeutics market is divided into vaccines, antiviral drugs, targeted therapy, immunosuppressants, chemotherapy, immunoglobulins, and corticosteroids.
The antiviral drugs segment accounted for a key share of the market in 2019 and is expected to grow at a rapid pace during the forecast period. The segment growth is attributed to increasing population with rising number of alcohol consumption, and increasing the prevalence of liver diseases.
However, the chemotherapy segment is estimated to expand at a robust growth rate during the forecast period due to advancement in medical diagnosis in the field.
Liver Diseases Therapeutics Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years due to the wide engagement in academic and research institutes initiating medical trial studies in the region.
The market of Asia Pacific, however, is expected to grow rapidly during the forecast period owing to supportive government initiatives in various countries of the region such as Japan and Australia.
Moreover, favorable government policies pertaining to drug price adjustment and the development of novel drugs for the treatment of liver diseases in the region present key drivers of the market growth in Asia Pacific.
Segments
Products
- Vaccines
- Antiviral Drugs
- Targeted Therapy
- Immunosuppressants
- Chemotherapy
- Immunoglobulins
- Corticosteroids
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Astellas Pharma Inc.
- Abbott Laboratories
- Bristol-Mayers Squibb
- GlaxoSmithKline plc.
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- Novartis International AG
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceuticals
- Pfizer Inc.
- Watson Pharmaceuticals
- Bausch Health Companies Inc.
Competitive Landscape
Key players competing in the global liver diseases therapeutics market are Astellas Pharma Inc.; Abbott Laboratories; Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F.
Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc.
The main market players are continuously engaged in market development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations.
For instance, GSK declared the US FDA approval of PROMACTA for the diagnosis of thrombocytopenia in patients in November 2012.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Liver Diseases Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Liver Diseases Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Liver Diseases Therapeutics Market - Supply Chain
4.5. Global Liver Diseases Therapeutics Market Forecast
4.5.1. Liver Diseases Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Liver Diseases Therapeutics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Liver Diseases Therapeutics Market Absolute $ Opportunity
5. Global Liver Diseases Therapeutics Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Liver Diseases Therapeutics Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
6. North America Liver Diseases Therapeutics Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Liver Diseases Therapeutics Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Liver Diseases Therapeutics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Liver Diseases Therapeutics Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
8. Europe Liver Diseases Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Liver Diseases Therapeutics Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Liver Diseases Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Liver Diseases Therapeutics Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Liver Diseases Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Liver Diseases Therapeutics Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Liver Diseases Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Liver Diseases Therapeutics Market: Market Share Analysis
11.2. Liver Diseases Therapeutics Distributors and Customers
11.3. Liver Diseases Therapeutics Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Astellas Pharma Inc.
11.4.2. Abbott Laboratories
11.4.3. Bristol-Mayers Squibb
11.4.4. GlaxoSmithKline plc.
11.4.5. Gilead Sciences, Inc.
11.4.6. F. Hoffmann-La Roche AG
11.4.7. Novartis International AG
11.4.8. Merck & Co., Inc.
11.4.9. Sanofi S.A.
11.4.10. Takeda Pharmaceuticals
11.4.11. Pfizer Inc.
11.4.12. Watson Pharmaceuticals
11.4.13. Bausch Health Companies Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
